logo
  

Tonix Pharma Stops Enrollment Of Fibromyalgia Trial; Stock Plunges

Tonix Pharmaceuticals Holding Corp. (TNXP) said that it has decided to stop enrollment in the Phase 3 RALLY study of TNX-102 SL --cyclobenzaprine HCl sublingual tablets-- 5.6 mg for the management of fibromyalgia.

The company said its decision follows a recommendation from an interim analysis indicating inadequate separation from placebo at week-14 in the first 50% of participants.

TNXP closed Friday regular trading at $0.98, down $0.03 or 2.97%. In the after-hours trade, the stock further dropped $0.33 or 33.78%.

The Independent Data Monitoring Committee (IDMC) recommended stopping the trial for futility as TNX-102 SL is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall change from baseline in daily diary pain severity scores between those treated with TNX-102 SL 5.6 mg (2x 2.8 mg tablets) and those receiving placebo.

Tonix said it remains blinded to the detailed interim analysis results and only received the recommendation made by the IDMC. Preliminary blinded safety data from these participants did not reveal any new safety signals, and the decision to discontinue enrolling new participants is not related to safety.

The company plans to continue studying those participants currently enrolled until completion and then proceed with a full analysis of the unblinded data, with the topline results expected to be reported in the fourth quarter of 2021, to determine the next steps in this program.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. air travel industry is going through its worst crisis since the troubled travel time during the peek pandemic struggles, with thousands of flights across the country being cancelled or getting delayed. The aviation crisis, as millions are preparing to travel during the upcoming July 4th holiday weekend, is mainly attributed to the staffing issues at airlines, ... The U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS has issued a public health alert for Siluriformes products imported by Carlstadt, New Jersey- based Grand BK Corp. The products were imported from Korea, a country ineligible to export Siluriformes products to the United States. Blount Fine Foods is recalling a limited amount of Panera at Home Southwest Corn Chowder citing undeclared wheat allergen, the U.S. Food and Drug Administration said. The recall involves a single lot of 16 oz. product with UPC Code 077958690812, lot number 042122-2K and "Use By" date of 6/30/22 that comes around 2,569 cases in total. The recall is limited to 1 SKU of 16 oz.
RELATED NEWS
Follow RTT